CN110199018B - 嵌合痘病毒组合物及其用途 - Google Patents

嵌合痘病毒组合物及其用途 Download PDF

Info

Publication number
CN110199018B
CN110199018B CN201780062335.8A CN201780062335A CN110199018B CN 110199018 B CN110199018 B CN 110199018B CN 201780062335 A CN201780062335 A CN 201780062335A CN 110199018 B CN110199018 B CN 110199018B
Authority
CN
China
Prior art keywords
nucleic acid
acid sequence
virus strain
cancer
vaccinia virus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201780062335.8A
Other languages
English (en)
Chinese (zh)
Other versions
CN110199018A (zh
Inventor
Y·方
N·陈
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
City of Hope
Original Assignee
City of Hope
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by City of Hope filed Critical City of Hope
Priority to CN202410528631.4A priority Critical patent/CN118853594A/zh
Priority to CN202410528486.XA priority patent/CN118834840A/zh
Publication of CN110199018A publication Critical patent/CN110199018A/zh
Application granted granted Critical
Publication of CN110199018B publication Critical patent/CN110199018B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/275—Poxviridae, e.g. avipoxvirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24151—Methods of production or purification of viral material

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN201780062335.8A 2016-08-09 2017-08-09 嵌合痘病毒组合物及其用途 Active CN110199018B (zh)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CN202410528631.4A CN118853594A (zh) 2016-08-09 2017-08-09 嵌合痘病毒组合物及其用途
CN202410528486.XA CN118834840A (zh) 2016-08-09 2017-08-09 嵌合痘病毒组合物及其用途

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662372408P 2016-08-09 2016-08-09
US62/372,408 2016-08-09
US201762519010P 2017-06-13 2017-06-13
US62/519,010 2017-06-13
PCT/US2017/046163 WO2018031694A1 (en) 2016-08-09 2017-08-09 Chimeric poxvirus compositions and uses thereof

Related Child Applications (2)

Application Number Title Priority Date Filing Date
CN202410528486.XA Division CN118834840A (zh) 2016-08-09 2017-08-09 嵌合痘病毒组合物及其用途
CN202410528631.4A Division CN118853594A (zh) 2016-08-09 2017-08-09 嵌合痘病毒组合物及其用途

Publications (2)

Publication Number Publication Date
CN110199018A CN110199018A (zh) 2019-09-03
CN110199018B true CN110199018B (zh) 2024-06-07

Family

ID=61163330

Family Applications (3)

Application Number Title Priority Date Filing Date
CN202410528631.4A Pending CN118853594A (zh) 2016-08-09 2017-08-09 嵌合痘病毒组合物及其用途
CN201780062335.8A Active CN110199018B (zh) 2016-08-09 2017-08-09 嵌合痘病毒组合物及其用途
CN202410528486.XA Pending CN118834840A (zh) 2016-08-09 2017-08-09 嵌合痘病毒组合物及其用途

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN202410528631.4A Pending CN118853594A (zh) 2016-08-09 2017-08-09 嵌合痘病毒组合物及其用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202410528486.XA Pending CN118834840A (zh) 2016-08-09 2017-08-09 嵌合痘病毒组合物及其用途

Country Status (11)

Country Link
US (2) US12084687B2 (enExample)
EP (1) EP3497209A4 (enExample)
JP (4) JP7023929B2 (enExample)
KR (3) KR20230113832A (enExample)
CN (3) CN118853594A (enExample)
AU (2) AU2017311380A1 (enExample)
BR (1) BR112019002646A2 (enExample)
CA (1) CA3033512A1 (enExample)
MX (1) MX2019001672A (enExample)
RU (2) RU2021128158A (enExample)
WO (1) WO2018031694A1 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2934532B1 (en) 2012-12-20 2019-10-23 Purdue Research Foundation Chimeric antigen receptor-expressing t cells as anti-cancer therapeutics
EP3261669B1 (en) 2015-02-25 2022-08-03 Memorial Sloan Kettering Cancer Center Use of inactivated nonreplicating modified vaccinia virus ankara (mva)as monoimmunotherapy or in combination with immune checkpoint blocking agents for solid tumors
US10548930B2 (en) 2015-04-17 2020-02-04 Memorial Sloan Kettering Cancer Center Use of MVA or MVAΔE3L as immunotherapeutic agents against solid tumors
WO2017147553A2 (en) 2016-02-25 2017-08-31 Memorial Sloan-Kettering Cancer Center Replication competent attenuated vaccinia viruses with deletion of thymidine kinase with and without the expression of human flt3l or gm-csf for cancer immunotherapy
IL261321B2 (en) 2016-02-25 2023-12-01 Memorial Sloan Kettering Cancer Center Recombinant MVA or MVADELE3L expressing human FLT3L and their use as immunotherapeutic agents against solid tumors
CA3019835A1 (en) 2016-04-08 2017-10-12 Purdue Research Foundation Methods and compositions for car t cell therapy
AU2017311380A1 (en) * 2016-08-09 2019-03-28 City Of Hope Chimeric poxvirus compositions and uses thereof
US11850262B2 (en) 2017-02-28 2023-12-26 Purdue Research Foundation Compositions and methods for CAR T cell therapy
CN111107872A (zh) 2017-05-12 2020-05-05 纪念斯隆-凯特林癌症中心 有用于癌症免疫疗法的牛痘病毒突变体
EP3664841A1 (en) 2017-08-11 2020-06-17 City of Hope Oncolytic virus expressing a car t cell target and uses thereof
CN120154716A (zh) 2018-01-22 2025-06-17 恩多塞特公司 Car t细胞的使用方法
CA3091674A1 (en) 2018-02-23 2019-08-29 Endocyte, Inc. Sequencing method for car t cell therapy
AU2019229653B2 (en) * 2018-03-07 2025-09-11 Transgene Parapoxvirus vectors
WO2019213173A1 (en) * 2018-04-30 2019-11-07 City Of Hope Neural stem cell compositions including chimeric poxviruses for cancer treatment
AU2019339535B2 (en) 2018-09-15 2025-11-20 Memorial Sloan Kettering Cancer Center Recombinant poxviruses for cancer immunotherapy
CN113583977B (zh) * 2020-04-30 2025-06-06 杭州康万达医药科技有限公司 可受微小rna调控的分离的重组溶瘤痘病毒及其应用
GB2614309A (en) 2021-12-24 2023-07-05 Stratosvir Ltd Improved vaccinia virus vectors
WO2023213763A1 (en) * 2022-05-02 2023-11-09 Transgene Poxvirus encoding a binding agent comprising an anti- pd-l1 sdab
TW202413636A (zh) 2022-08-18 2024-04-01 法商傳斯堅公司 嵌合痘病毒
WO2024245722A2 (en) * 2023-05-26 2024-12-05 Probiogen Ag Rapid selection system for the generation of recombinant enveloped viruses
WO2025184411A1 (en) 2024-02-27 2025-09-04 Calidi Biotherapeutics (Nevada), Inc. Serum-resistant eev viruses and uses thereof
CN120718864B (zh) * 2025-08-28 2025-11-28 山东农业大学 一种高度不成熟鸭坦布苏病毒及其培养方法和应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6352856B1 (en) * 1998-01-16 2002-03-05 Baxter Vaccine Ag Chimeric poxvirus comprising sequences of a retroviral vector component
CN1839201A (zh) * 2003-06-18 2006-09-27 吉恩勒克斯公司 修饰的重组痘苗病毒及其它微生物,及其应用
WO2015103438A2 (en) * 2014-01-02 2015-07-09 Genelux Corporation Oncolytic virus adjunct therapy with agents that increase virus infectivity

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001072995A2 (en) 2000-03-28 2001-10-04 University Of Rochester Methods of producing a library and methods of selecting polynucletides
US7300658B2 (en) * 2002-11-25 2007-11-27 Bavarian Nordic A/S Recombinant poxvirus comprising at least two compox ATI promoters
US8052968B2 (en) * 2006-10-16 2011-11-08 Genelux Corporation Modified vaccinia virus strains for use in diagnostic and therapeutic methods
NZ584201A (en) * 2007-11-19 2012-06-29 Transgene Sa Poxviral oncolytic vectors comprising a defective f2l gene
JP5652830B2 (ja) * 2010-04-09 2015-01-14 国立大学法人 東京大学 マイクロｒｎａ制御組換えワクシニアウイルス及びその使用
CN114262690A (zh) 2011-04-15 2022-04-01 吉恩勒克斯公司 减毒的痘苗病毒的克隆毒株及其使用方法
WO2013172721A1 (en) * 2012-05-18 2013-11-21 Wise Lyn Marie Combination treatments and compositions for wound healing
AU2017311380A1 (en) * 2016-08-09 2019-03-28 City Of Hope Chimeric poxvirus compositions and uses thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6352856B1 (en) * 1998-01-16 2002-03-05 Baxter Vaccine Ag Chimeric poxvirus comprising sequences of a retroviral vector component
CN1839201A (zh) * 2003-06-18 2006-09-27 吉恩勒克斯公司 修饰的重组痘苗病毒及其它微生物,及其应用
WO2015103438A2 (en) * 2014-01-02 2015-07-09 Genelux Corporation Oncolytic virus adjunct therapy with agents that increase virus infectivity

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
"A Novel Strategy for Determining Protective;MERCER A A等;《VIROLOGY》;19970303;193-200 *
"Genome Scale Patterns of Recombination between Coinfecting Vaccinia Viruses";L.QIN 等;《JOURNAL OF VIROLOGY》;20140226;第88卷(第10期);5277-5286 *
:"Genetic studies with mammalian poxviruses;WOODROOFE G M等;《VIROLOGY》;19601001;272-282 *

Also Published As

Publication number Publication date
MX2019001672A (es) 2019-06-06
CA3033512A1 (en) 2018-02-15
RU2019106319A (ru) 2020-09-17
US20250084384A1 (en) 2025-03-13
US20190218522A1 (en) 2019-07-18
EP3497209A4 (en) 2020-07-29
KR20190038626A (ko) 2019-04-08
CN118834840A (zh) 2024-10-25
KR20250067190A (ko) 2025-05-14
JP2019524131A (ja) 2019-09-05
RU2019106319A3 (enExample) 2021-03-17
KR20230113832A (ko) 2023-08-01
EP3497209A1 (en) 2019-06-19
WO2018031694A1 (en) 2018-02-15
JP7395628B2 (ja) 2023-12-11
RU2757002C2 (ru) 2021-10-08
CN118853594A (zh) 2024-10-29
JP2025072482A (ja) 2025-05-09
AU2023270200A1 (en) 2024-01-25
KR102557818B1 (ko) 2023-07-20
AU2017311380A1 (en) 2019-03-28
JP7023929B2 (ja) 2022-02-22
JP2024026191A (ja) 2024-02-28
BR112019002646A2 (pt) 2019-10-08
JP2022065034A (ja) 2022-04-26
RU2021128158A (ru) 2022-04-07
US12084687B2 (en) 2024-09-10
CN110199018A (zh) 2019-09-03
JP7631485B2 (ja) 2025-02-18

Similar Documents

Publication Publication Date Title
CN110199018B (zh) 嵌合痘病毒组合物及其用途
RU2757933C2 (ru) Новые генно-инженерные вирусы осповакцины
CN111163803B (zh) 表达car t细胞靶物的溶瘤病毒及其用途
KR102243727B1 (ko) 유전자 표적화 및 형질 스태킹을 위한 조작된 트랜스진 통합 플랫폼 (etip)
KR20230111189A (ko) 재프로그램 가능한 iscb 뉴클레아제 및 이의 용도
KR20240019791A (ko) 원형 rna 조성물 및 방법
KR20210132003A (ko) 변형된 오르토폭스 바이러스 벡터
CN113271955A (zh) 用于细胞介导的溶瘤病毒疗法的增强的系统
AU2017353868B2 (en) Synthetic chimeric poxviruses
KR20150052241A (ko) 식물 생성을 위한 형광 활성화 세포 분류 (facs) 강화
CN116348135A (zh) 基于重组痘病毒的抗SARS-CoV-2病毒疫苗
KR101234062B1 (ko) 림프구 내 유전자 도입용 재조합 바이러스 벡터
CN112243377A (zh) 用于治疗和预防细菌相关的癌症的噬菌体
KR20230012583A (ko) 합성 변형된 백시니아 앙카라 (sMVA) 기반 코로나바이러스 백신
KR20200131863A (ko) 암 면역요법을 위한, 면역 관문 차단을 발현하는 종양용해 백시니아 바이러스
KR20220148823A (ko) 천연 또는 합성 dna에 의해 생산된 폭스바이러스-기반 벡터 및 그의 용도
KR20240021274A (ko) 반코마이신 내성 장구균에 대한 박테리오파지
CN117222418A (zh) 增强肿瘤中的hla单倍型表达多样性以扩大肿瘤细胞对tcr-t疗法的敏感性的方法
CN112261951A (zh) 包含合成嵌合痘苗病毒的干细胞及其使用方法
KR102016919B1 (ko) 신규한 살모넬라균 특이 박테리오파지 sc1 및 이를 포함하는 항균 조성물
TWI902763B (zh) 基於重組痘病毒之抗SARS-CoV-2病毒疫苗
HK40042130A (en) Stem cells comprising synthetic chimeric vaccinia virus and methods of using them
CN117999090A (zh) 鼠痘病毒用于癌症免疫治疗和疫苗的用途
HK40078138A (en) Poxvirus-based vectors produced by natural or synthetic dna and uses thereof
HK40042802A (en) Bacteriophage for treatment and prevention of bacteria-associated cancers

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant